Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapy Guidances Will Focus On Specific Diseases, Gottlieb Says

Executive Summary

US FDA's first such guidance will focus on hemophilia, commissioner tells Congress.

Advertisement

Related Content

Gene Therapies Need Long-Term Follow-Up Plan From Outset Or Risk Clinical Hold
The Luxturna Model: Spark’s Approach To Retinal Disease Endpoint Embraced In Gene Therapy Guidance
Gottlieb On Gene Therapies: 'Very Seductive' To Think About Accelerated Approval Pathway
US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say
How To Conduct A Multi-Company Trial For Rare Pediatric Diseases
US FDA May Create Immunology, Neuroscience Centers Of Excellence
Keeping Track: Another Gene Therapy Approval, Several Priority Review Designations, And Many Resubmissions
Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform
FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development
Round 2 'Innovation' Bills Adopted; Funding Fight Ahead

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122103

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel